Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03LUF
|
|||
| Drug Name |
CD137 CAR-T Cell
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1/2 | [1] | |
| B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1/2 | [1] | ||
| Company |
Wuhan Sian Medical Technology Co., Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Co-stimulatory molecule 4-1BB (CD137) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.